Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Patients with pre-existing cardiovascular conditions, uncontrolled hypertension, or structural cardiac abnormalities require particularly cautious evaluation, and stimulants may be contraindicated in certain high-risk individuals
Semaglutide was the first to succeed in this effort
However, plaintiffs allege that the risks of severe outcomes were not adequately disclosed at the time they were prescribed the medication
As patents expire and potential generic or biosimilar versions emerge (e.g., generic liraglutide by Teva in 2024 ( [68] )), costs might come down, but for newer agents like semaglutide or tirzepatide, it could be years
Manufactured in a cGMP registered facility with high manufacturing and sourcing standards
While neither medication has demonstrated cardiovascular benefit in dedicated outcome trials yet, Mounjaros longer clinical experience provides more confidence regarding safety in this population
US$ 23.93
US$ 26.97
US$ 24.83
US$ 29.67
US$ 22.02
US$ 20.21
US$ 25.16
